Abstract
TOP-077 - Safety, tolerability, and preliminary efficacy of ascending doses of Human Allogeneic Liver-derived Progenitor Cells (HepaStem®) in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have